Veradermics, Incorporated reported positive topline Phase 2 data from Study ‘207’ of VDPHL01, an extended-release oral minoxidil tablet, in women with mild-to-moderate pattern hair loss. Female participants receiving 4.5 mg once or twice daily for 6 months showed objective hair growth and high patient-reported benefit.
Average non-vellus Target Area Hair Count increased 22.7 hairs/cm² in the once-daily arm and 23.3 hairs/cm² in the twice-daily arm at Month 6. On the Androgenetic Alopecia Impact Rating Scale, 88.9% (once-daily) and 90.0% (twice-daily) of women reported ‘improved’ or ‘much improved’ hair coverage, while investigators graded 100% and 90% of participants, respectively, as improved. Improvement was already seen at Month 2, with investigators and patients reporting benefits in 67.2% and 63.2% of participants.
VDPHL01 was generally well tolerated through Month 6, with no treatment-related serious adverse events and no cardiac adverse events of special interest; the most common adverse events were hypertrichosis and peripheral edema. Veradermics is running registration-directed Phase 2/3 trials in male and female pattern hair loss, with key topline readouts expected in 2026–2027.
Veradermics, Inc ownership disclosure: Viking Global Investors and affiliated entities report shared beneficial ownership of 1,690,555 shares of Common Stock. The filing states these holdings represent 4.5% of the class based on 37,340,290 shares outstanding as of March 31, 2026.
The schedule details the allocation across affiliated vehicles: VGOP and related GP entities beneficially own 1,014,331 shares (2.7%), while VGOD and related GP entities beneficially own 676,224 shares (1.8%). The amendment also removes David C. Ott as a reporting person effective March 31, 2026.
Veradermics, Incorporated reported a net loss of $27.2 million for the three months ended March 31, 2026, as it increased investment in late-stage dermatology programs. Research and development expenses rose to $20.9 million and general and administrative costs reached $8.9 million, reflecting expanded clinical activity and public-company readiness.
The company strengthened its balance sheet with an IPO in February 2026 generating net proceeds of $269.1 million, bringing cash, cash equivalents and marketable securities to $390.8 million as of March 31, 2026. Subsequent May 2026 follow-on and private offerings added $472.0 million in gross proceeds to support development of lead candidate VDPHL01 and its broader dermatology pipeline.
Veradermics, Inc. reported a larger net loss for the first quarter of 2026 as it accelerated late-stage development of its lead hair-loss drug VDPHL01 and strengthened its balance sheet. Net loss was $27.2 million, compared with $12.4 million a year earlier, driven by higher R&D and G&A spending.
Cash, cash equivalents and marketable securities were $390.8 million as of March 31, 2026, reflecting proceeds from an upsized IPO in February. A follow-on offering completed after quarter-end raised an additional $472.0 million in gross proceeds, contributing to an aggregate $766.8 million raised in 2026 and a projected cash runway into 2030.
The company highlighted positive topline results from Part A of Phase 2/3 Study ‘302’ of oral, extended-release minoxidil tablet VDPHL01 in male pattern hair loss, completion of enrollment in confirmatory Phase 3 Study ‘304’, and ongoing enrollment in Phase 2/3 Study ‘306’ in women, positioning VDPHL01 as a potential first-in-class non-hormonal oral treatment.
Veradermics, Incorporated ownership disclosure: Citadel Advisors LLC and related reporting persons report shared beneficial ownership of 1,870,775 shares of Common Stock. The filing states this position represents 4.5% of shares outstanding based on 41,183,254 Shares outstanding as of May 1, 2026.
The joint filing lists the reporting group (Citadel Advisors, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities entities and Kenneth Griffin) and details shared voting and dispositive power over the reported shares. Signature blocks show the statement was filed on behalf of the reporting persons.
Suvretta Capital–related funds filed Amendment No. 1 to their Schedule 13D on Veradermics, Inc., updating their ownership and warrant holdings. Suvretta Capital Management and Aaron Cowen report beneficial ownership of 4,172,121 shares of common stock, representing 9.9% of the class, including 3,151 shares issuable upon exercise of Pre-Funded Warrants.
Averill Master Fund, Ltd. reports 3,650,103 shares, or 8.7% of the class, and Averill Madison Master Fund, Ltd. reports 522,018 shares, or 1.2%. The amendment describes an April 29, 2026 Securities Purchase Agreement under which Averill Master Fund acquired 149,000 Pre-Funded Warrants and Averill Madison Master Fund acquired 151,000, each at $99.99999 per warrant with a $0.00001 exercise price, subject to a Beneficial Ownership Limitation of generally 9.99%, or up to 19.99% upon election.
Veradermics, Inc. investment entities reported new derivative awards rather than open-market trades. On May 1, 2026, reporting persons including Suvretta Capital Management, LLC and Averill funds reported the indirect acquisition of two blocks of Pre-Funded Warrants for 151,000 and 149,000 underlying shares of Veradermics common stock. These transactions are coded as grants or awards, so they increase indirect exposure to Veradermics without reflecting discretionary buying or selling in the open market.
Veradermics, Incorporated received an updated ownership filing from Longitude-affiliated investment funds and their managers. The group reports beneficial ownership of Veradermics common stock through several Delaware entities and two individual managers, reflecting coordinated investment positions.
Longitude Venture Partners V, L.P. and related entities report 2,600,399 shares, or 6.3% of the common stock, while Longitude 103.8 East, L.P. and its affiliates report 2,053,474 shares, or 5.0%. Individually, Patrick G. Enright and Juliet Tammenoms Bakker are each deemed to beneficially own 4,653,873 shares, representing 11.3% of Veradermics’ 41,184,080 shares outstanding. The filing details shared voting and dispositive power across these funds and clarifies that each reporting person generally disclaims beneficial ownership beyond their pecuniary interest.
Seven Fleet Master Fund LP and related entities filed a Schedule 13D on Veradermics, Inc., reporting beneficial ownership of 80,000 common shares, or 0.2% of 41,184,080 shares outstanding. The stake, held through Seven Fleet Master Fund, was acquired mainly in open-market and follow-on offering purchases.
The fund paid an aggregate purchase price of about $8,000,000 for these shares, including 80,000 shares bought at $100.00 per share in the issuer’s follow-on offering on May 1, 2026. The investors state they viewed the stock as undervalued and an attractive opportunity when purchased.
The filing outlines a flexible strategy: the group may buy more shares, sell shares, or engage in hedging, and may communicate with management, the board, other shareholders, or potential acquirers about capital allocation, ownership structure, a possible sale of the company or its parts, and board or operational changes.
Seven Fleet Capital Management LP, as a reporting person for Veradermics, Inc., has filed an initial Form 3 showing indirect ownership of 80,000 shares of common stock held by managed funds. The filing notes that Dr. Brian Liu may be deemed to control the reporting entities and may be deemed to beneficially own these shares, but he disclaims beneficial ownership except to the extent of any indirect pecuniary interest.